Big Pharma Has Raised The Prices Of 3,400 Drugs So Far This Year

| July 29, 2019

article image
In the first half of 2019, major pharmaceutical companies have raised the price of 3,400 different medications, with several dozen of those price increases being in the triple digit percentage. The average cost has increased by more than 4 times the rate of inflation, and the only reason this is happening is because they know they can get away with it. Ring of Fire’s Farron Cousins discusses this.

Spotlight

Nordic Drugs

Few, if any, other players in the pharmaceutical market have the same level of knowledge of the specific conditions that apply in the Nordic region. To build further value through our unique concept, we are in constant search for strong and sustainable partnerships with companies that have the intention of expanding business into the Nordic region.

OTHER ARTICLES

Global Antiviral Drugs Market Growth: Is Antiviral Drug the Best Coronavirus Treatment?

Article | April 9, 2020

The global antiviral drugs market has witnessed a rapid surge in demand due to the ongoing Covid-19 pandemic worldwide. So is antiviral drug the best coronavirus treatment? It is still too early to have that conclusion as many medical research and clinical trials are still trying to find the effectiveness and potential side effects of using antiviral drugs to treat coronavirus. But experts believe that antiviral drug might be the best hope for reduce the coronavirus transmission around the world at this stage. However, due to the current difficult situation of the supply chain in many lockdown countries and regions, there is a global shortage on the antiviral drugs supply. With researchers and manufacturers working hard to find and provide effective coronavirus treatment, it is expected that the global antiviral drugs market will have a significant growth over the near future. Antiviral drugs are a type of medication used specifically for treating viral infections, such as human immunodeficiency virus (HIV), hepatitis, and influenza.

Read More

The Future of Pharma Beyond Blockbusters

Article | April 9, 2020

We’ve all heard the saying “treat the patient, not the disease”, and this couldn’t be truer in today’s ever-changing pharmaceutical landscape. We are living in a time of revolution – advancements in genomics and technology are improving our ability to develop precise drugs and targeted therapies, rather than focusing on a one size fits all approach. Each individual’s genetic makeup is slightly different from everyone else’s,

Read More

Merck’s Patient-Centric Clinical Trial Recruiting

Article | April 9, 2020

Everyone in pharma knows that product success depends on the results of clinical trials — but we don’t usually hear from the people who are involved in running them. Recently, four Clinical Research Managers (CRM) from Merck (known as MSD outside the United States and Canada) discussed how Merck is overcoming the barriers to clinical trial recruitment by adopting a patient-centric process — a model that affects their trials top to bottom, from design through implementation. Each of the panel members manages clinical trials, serving as the main point of interaction with the Clinical Research Associates (CRAs) on research requirements, goals, and resources, including recruiting and retention.

Read More

WALGREEN’S IN HOT WATER OVER PHONY PHARMACIST

Article | April 9, 2020

The drugstore chain agreed to pay $7.5 million in fines after an unlicensed pharmacist at several San Francisco Bay locations illegally filled more than 700,000 prescriptions over a ten-year period. According to California prosecutors, Kim Thien Le stole license numbers from other pharmacists to fill prescriptions for Fentanyl, morphine, and other painkillers. Le pleaded guilty to multiple felony impersonation counts. Walgreen’s agreed to the settlement to avoid being charged with consumer fraud in Alameda and Santa Anna Counties. Prosecutors alleged that Walgreen’s failed to verify Le’s license and did not conduct a thorough background check. The company insisted it has taken remedial measures.

Read More

Spotlight

Nordic Drugs

Few, if any, other players in the pharmaceutical market have the same level of knowledge of the specific conditions that apply in the Nordic region. To build further value through our unique concept, we are in constant search for strong and sustainable partnerships with companies that have the intention of expanding business into the Nordic region.

Events